1. IDEC Pharmaceuticals Corporation (2001) Rituxan (rituximab). IDEC Pharmaceuticals Corporation, San Diego, vol 19, p 2
2. U.S. Food and Drug Administration Center for Biologics Evaluation and Research (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use. J Immunother 20:214–243
3. IDEC Pharmaceuticals Corporation (1996) A phase I/II clinical trial of yttrium-[90]-labeled IDEC-2B8 given every 6 to 8 weeks to patients with B-cell lymphoma. BB-IND 4850 and 4851. IDEC Pharmaceuticals Corporation, San Diego, vol 106-01-01
4. IDEC Pharmaceuticals Corporation (2000) A phase II, open-label, multicenter trial to evaluate the safety and efficacy of IDEC-Y2B8 radioimmunotherapy of relapsed or refractory low-grade or follicular B-cell non-Hodgkin's lymphoma in patients with mild thrombocytopenia. IDEC Pharmaceuticals Corporation, San Diego, vol 106-05
5. IDEC Pharmaceuticals Corporation (2000) A phase III, open-label, nonrandomized controlled, multicenter trial to evaluate the safety and efficacy of IDEC-Y2B8 radioimmunotherapy in patients with B-cell non-Hodgkin's lymphoma who are refractory to prior rituximab therapy. IDEC Pharmaceuticals Corporation, San Diego